Penny Tom Sells 65,000 Shares of Equillium (NASDAQ:EQ) Stock

Equillium, Inc. (NASDAQ:EQ) insider Penny Tom sold 65,000 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $2.95, for a total transaction of $191,750.00. Following the transaction, the insider owned 65,000 shares of the company’s stock, valued at approximately $191,750. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Equillium Trading Up 2.1%

Shares of NASDAQ:EQ traded up $0.06 during midday trading on Friday, reaching $2.90. 853,917 shares of the company were exchanged, compared to its average volume of 480,896. The business’s fifty day moving average is $2.09 and its two-hundred day moving average is $1.63. Equillium, Inc. has a one year low of $0.27 and a one year high of $3.10. The stock has a market cap of $183.37 million, a PE ratio of -9.06 and a beta of 1.67.

Equillium (NASDAQ:EQ) last issued its earnings results on Wednesday, May 13th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). As a group, sell-side analysts expect that Equillium, Inc. will post -0.24 EPS for the current year.

Wall Street Analyst Weigh In

EQ has been the subject of several research reports. Leerink Partners upgraded shares of Equillium from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $1.00 to $6.00 in a research report on Thursday. Zacks Research upgraded shares of Equillium to a “hold” rating in a report on Thursday, February 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Equillium in a report on Friday, March 27th. Wall Street Zen lowered shares of Equillium from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $7.00 target price on shares of Equillium in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.57.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in EQ. Aberdeen Group plc purchased a new position in Equillium in the 3rd quarter worth about $543,000. Vanguard Group Inc. increased its stake in Equillium by 59.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company’s stock worth $1,879,000 after buying an additional 489,855 shares during the period. Persistent Asset Partners Ltd purchased a new position in Equillium in the 3rd quarter worth about $99,000. Two Sigma Investments LP purchased a new position in Equillium in the 3rd quarter worth about $190,000. Finally, ADAR1 Capital Management LLC purchased a new position in Equillium in the 3rd quarter worth about $7,951,000. Hedge funds and other institutional investors own 27.05% of the company’s stock.

Key Headlines Impacting Equillium

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: Leerink Partners upgraded Equillium from market perform to outperform and lifted its price target to $6.00, suggesting meaningful upside from current levels. Leerink Upgrades Equillium (EQ) to Outperform
• Positive Sentiment: Roth Mkm reiterated a buy rating and set a $12.00 target, reinforcing a bullish view on Equillium’s pipeline and valuation. Equillium Receives Buy Rating from Roth Mkm
• Positive Sentiment: Equillium announced it will participate in the 2026 Jefferies Global Healthcare Conference, which could provide a catalyst if management shares favorable clinical or strategic updates. Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
• Positive Sentiment: Shareholders approved a reverse split and capital changes at the annual meeting, a step that can help maintain Nasdaq compliance and potentially improve the company’s capital structure. Equillium Shareholders Approve Reverse Split and Capital Changes
• Neutral Sentiment: Short interest was reported at 0 shares, indicating no meaningful bearish positioning in the latest update, though the figure appears unusual and may not be a reliable market signal. Short interest update
• Negative Sentiment: COO Christine Zedelmayer sold a combined 95,833 shares over two transactions, and insider Penny Tom sold 65,000 shares; although both were made under pre-arranged 10b5-1 plans, insider selling can still pressure sentiment. SEC Form 4 insider sales filing

About Equillium

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.